Acurx Pharmaceuticals, Inc.
ACXP
$3.48
$0.206.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.93% | -31.59% | -21.51% | 2.00% | 37.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.87% | -40.06% | -25.99% | -3.22% | 29.22% |
| Operating Income | 43.87% | 40.06% | 25.99% | 3.22% | -29.22% |
| Income Before Tax | 44.21% | 40.23% | 26.03% | 3.26% | -29.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.21% | 40.23% | 26.03% | 3.26% | -29.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.21% | 40.23% | 26.03% | 3.26% | -29.18% |
| EBIT | 43.87% | 40.06% | 25.99% | 3.22% | -29.22% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 60.64% | 53.29% | 40.03% | 22.87% | -3.13% |
| Normalized Basic EPS | 60.64% | 53.29% | 40.03% | 22.87% | -3.13% |
| EPS Diluted | 60.64% | 53.29% | 40.03% | 22.87% | -3.13% |
| Normalized Diluted EPS | 60.64% | 53.29% | 40.03% | 22.87% | -3.13% |
| Average Basic Shares Outstanding | 51.69% | 32.67% | 26.88% | 27.47% | 26.95% |
| Average Diluted Shares Outstanding | 51.69% | 32.67% | 26.88% | 27.47% | 26.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |